» Articles » PMID: 34491321

The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease

Abstract

Background And Aims: Protein profiling in patients with inflammatory bowel diseases [IBD] for diagnostic and therapeutic purposes is underexplored. This study analysed the association between phenotype, genotype, and the plasma proteome in IBD.

Methods: A total of 92 inflammation-related proteins were quantified in plasma of 1028 patients with IBD (567 Crohn's disease [CD]; 461 ulcerative colitis [UC]) and 148 healthy individuals to assess protein-phenotype associations. Corresponding whole-exome sequencing and global screening array data of 919 patients with IBD were included to analyse the effect of genetics on protein levels (protein quantitative trait loci [pQTL] analysis). Intestinal mucosal RNA sequencing and faecal metagenomic data were used for complementary analyses.

Results: Thirty-two proteins were differentially abundant between IBD and healthy individuals, of which 22 proteins were independent of active inflammation; 69 proteins were associated with 15 demographic and clinical factors. Fibroblast growth factor-19 levels were decreased in CD patients with ileal disease or a history of ileocecal resection. Thirteen novel cis-pQTLs were identified and 10 replicated from previous studies. One trans-pQTL of the fucosyltransferase 2 [FUT2] gene [rs602662] and two independent cis-pQTLs of C-C motif chemokine 25 [CCL25] affected plasma CCL25 levels. Intestinal gene expression data revealed an overlapping cis-expression [e]QTL-variant [rs3745387] of the CCL25 gene. The FUT2 rs602662 trans-pQTL was associated with reduced abundances of faecal butyrate-producing bacteria.

Conclusions: This study shows that genotype and multiple disease phenotypes strongly associate with the plasma inflammatory proteome in IBD, and identifies disease-associated pathways that may help to improve disease management in the future.

Citing Articles

Integrating multi-omics data to reveal the host-microbiota interactome in inflammatory bowel disease.

Su F, Su M, Wei W, Wu J, Chen L, Sun X Gut Microbes. 2025; 17(1):2476570.

PMID: 40063366 PMC: 11901428. DOI: 10.1080/19490976.2025.2476570.


Network Mendelian randomisation analysis deciphers protein pathways linking type 2 diabetes and gastrointestinal disease.

Geng J, Ruan X, Wu X, Chen X, Fu T, Gill D Diabetes Obes Metab. 2024; 27(2):866-875.

PMID: 39592890 PMC: 7617254. DOI: 10.1111/dom.16087.


Plasma Inflammatory Proteome Profile in a Cohort of Patients with Recurrent Vulvovaginal Candidiasis in Kenya.

Rosati D, Ricano Ponce I, Omosa-Manyonyi G, Bruno M, Kamau N, Jaeger M J Fungi (Basel). 2024; 10(9).

PMID: 39330398 PMC: 11433550. DOI: 10.3390/jof10090638.


Butyrate protects the intestinal barrier by upregulating Fut2 expression via MEK4-JNK signaling pathway activation.

Zhang D, Huang Z, Liu X, Ding X, Li L, He Y Pediatr Res. 2024; 97(1):128-137.

PMID: 39134757 DOI: 10.1038/s41390-024-03419-6.


Flavonoids-Enriched Vegetal Extract Prevents the Activation of NFκB Downstream Mechanisms in a Bowel Disease In Vitro Model.

Corbetta P, Lonati E, Pagliari S, Mauri M, Cazzaniga E, Botto L Int J Mol Sci. 2024; 25(14).

PMID: 39063111 PMC: 11277009. DOI: 10.3390/ijms25147869.


References
1.
Opstad T, Brusletto B, Arnesen H, Pettersen A, Seljeflot I . Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease. Immunobiology. 2016; 222(2):169-175. DOI: 10.1016/j.imbio.2016.10.007. View

2.
Enroth S, Johansson A, Bosdotter Enroth S, Gyllensten U . Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. Nat Commun. 2014; 5:4684. PMC: 4143927. DOI: 10.1038/ncomms5684. View

3.
Zhernakova D, Le T, Kurilshikov A, Atanasovska B, Bonder M, Sanna S . Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome. Nat Genet. 2018; 50(11):1524-1532. PMC: 6241851. DOI: 10.1038/s41588-018-0224-7. View

4.
Berkhout L, lAmi M, Ruwaard J, Hart M, Ooijevaar-De Heer P, Bloem K . Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Sci Transl Med. 2019; 11(477). DOI: 10.1126/scitranslmed.aat3356. View

5.
Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S . Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011; 39(15):e102. PMC: 3159481. DOI: 10.1093/nar/gkr424. View